AD Pipeline Watch: First Patient Dosed in Part B of Phase 2 APEX Trial of Apogee’s APG777 in Moderate-to-Severe AD
The first patient has been dosed in Part B of the Phase 2 APEX clinical trial of APG777 in patients with moderate-to-severe atopic dermatitis (AD), and enrollment is complete in Part A, Apogee Therapeutics reports. APEX is a Phase 2 randomized, placebo-controlled clinical trial evaluating APG777, a novel, subcutaneous (SQ) extended half-life monoclonal antibody (mAb) […]